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osting by EAbstract A variety of treatment options are available for the treatment of diabetic macular edema.
They include laser photocoagulation, anti-VEGF drugs, intravitreal steroids, and vitrectomy with
or without release of vitreoretinal traction. A full understanding of the physiological mechanisms
of these treatment modalities allows sensible combination of treatment options.
Retinal photocoagulation has repeatedly been shown to improve retinal oxygenation, as does vit-
rectomy. Oxygen naturally reduces VEGF production and thereby decreases leakage of plasma pro-
teins from capillaries into the tissue. In addition, vitrectomy allows faster clearance of cytokines,
such as VEGF, from the retina into the vitreous cavity. The VEGF-lowering effect of photocoag-
ulation and vitrectomy can be augmented with anti-VEGF drugs and corticosteroids reduce the
effect of VEGF on capillary permeability.
Starling’s law explains vasogenic edema, which is controlled by osmotic and hydrostatic gradients
between vessel and tissue. It explains how VEGF-induced vascular permeability causes plasma pro-
tein to leak into the tissue interstitial space, thus decreasing the osmotic pressure gradient between
vessel and tissue, resulting in water accumulation, i.e. edema. This is reversed by reducing VEGF
production, which is achieved with laser treatment; or by removing VEGF with antibodies or vit-
rectomy; or by reducing the permeability effect with steroids.
At the same time, Starling’s law takes into account hemodynamic changes that affect the hydro-
static gradient. High arterial blood pressure and hypoxic vasodilatation increase the hydrostatic
pressure in the microcirculation, which increases water ﬂux from vessel to tissue and induce4831.
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144 E. Stefa´nssonedema. Treatment of arterial hypertension or reversal of retinal hypoxia with laser reverses this
pathophysiology and reduces edema.
Newton’s third law explains, that vitreoretinal traction decreases hydrostatic tissue pressure in
the retina, increases the pressure gradient between vessel and tissue, and stimulates water ﬂuxes
from vessel into tissue, leading to edema. Release of vitreoretinal traction reverses this mechanism
and reduces edema.
ª 2009 King Saud University. All rights reserved.Contents
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Diabetic macular edema (DME) remains the most common
cause of reduced vision in diabetic patients. About one diabetic
patient in four can be expected to develop diabetic macular
edema in a lifetime (Klein et al., 2009; Kristinsson, 1997; Ste-
fansson et al., 2000), and this puts the visual acuity at risk.
The treatment of diabetic macular edema has developed
over the last 30 years or so. Focal or grid macular photocoag-
ulation was established as an effective treatment in the 1980s
and remains the gold standard and the treatment of ﬁrst choice
(O’Doherty et al., 2008). Additional treatment modalities have
emerged in recent years and have shown themselves to be effec-
tive. These include intravitreal steroids (Gomez-Ulla et al.,
2006; Kim et al., 2009), and intravitreal antibodies for vascular
endothelial growth factor (VEGF) (Fang et al., 2008; Kook
et al., 2008; Soliman et al., 2008), vitrectomy (Kim et al.,
2009; Figueroa et al., 2008; Hartley et al., 2008) and release
of vitreoretinal traction (Lewis et al., 1992).
Treatment of arterial hypertension has been shown to play
a role in reducing diabetic macular edema (Klein et al., 2009;
Wong et al., 2008). With several effective treatment options
available for DME the question becomes how best to combine
these to maximize effect and minimize adverse side effects
(Kang et al., 2007; Faghihi et al., 2008; Margolis et al.,
2008). It is a daunting task to perform the entire permutation
of clinical trials to optimize the combination of the various
treatment modalities, such as laser, vitrectomy, anti-VEGF
and steroids. Another way to approach this issue is to try to
understand the pathophysiology of diabetic macular edema
and how this is inﬂuenced by the various treatment methods
and thus make sense of the various combinations in treatment.
This issue has been extensively discussed in a recent article
(Stefansson, 2009) and will be brieﬂy reviewed here.2. Physiology of diabetic macular edema
Edema is deﬁned as an abnormal accumulation of water in a
tissue. In vasogenic edema the water accumulates in the inter-
stitial space, whereas water accumulates within cells in cyto-
toxic or ischemic edema. The physiology of vasogenic edema
is based on the water exchange between the blood in the vas-
culature and the water in the interstitial space in the tissue.
We will focus on vasogenic edema in this discussion.
The physiology of vasogenic edema has been understood in
medicine for more than a century. Starling in 1896 deﬁned the
forces that transport water between the vascular space (blood)
and tissue interstitial space. The forces are hydrostatic and os-
motic. The hydrostatic pressure in the blood is established by
the pumping activity of the heart. The difference in hydrostatic
pressure between the blood in the vasculature and the hydro-
static pressure in the tissue (in the eye the intraocular pressure)
deﬁnes the hydrostatic pressure gradient which pushes water
from the vasculature into the tissue interstitial space and in-
duces edema.
The opposite force is the osmotic gradient which is based
on the osmotic activity of the macromolecules, mostly albu-
min, in the blood, versus osmotically active molecules in the
tissue interstitial space. Due to the concentration of albumin,
the osmotic pressure in the blood is higher than that in the tis-
sue interstitial space and this pulls water back from the tissue
interstitial space into the blood circulation and reduces edema.
In the normal situation the hydrostatic pressure gradient
and the osmotic pressure gradients between blood vessel and
tissue are equal and opposite and there is no net movement
of water between these compartments. This balance can be up-
set if either pressure gradient is altered. Either an increase in the
hydrostatic pressure gradient or a decrease in the osmotic pres-
sure gradient induces edema. Starling’s law is the foundation on
Diabetic macular edema 145which we can understand the pathophysiology of edema forma-
tion in any tissue including the retina, and also how this is inﬂu-
enced by treatment (Stefansson, 2009).
Diabetic macular edema is always associated with increased
leakage of the macular capillaries as is seen on ﬂuorescein angi-
ography and ﬂuorophotometry (Soliman et al., 2008). The
physiological importance of capillary leakage is the leakage
of macromolecules, predominantly albumin, from the blood
into the tissue interstitial space. The accumulation of albumin
in the tissue interstitial space increases the osmotic pressure in
the tissue and reduces the osmotic pressure difference between
the tissue interstitial space and blood. The smaller osmotic
pressure gradient is less effective in pulling water back to the
blood stream from the tissue interstitial space and conse-
quently water accumulates in the tissue interstitial space and
edema develops.
Vascular endothelial growth factor is very effective in
increasing the permeability or leakage of retinal capillaries
and may be primarily responsible for the increased leakage
of retinal capillaries in diabetic retinopathy (Shimada et al.,
2008). Therefore, an essential aim in the treatment of diabetic
macular edema is to reduce the concentration of VEGF. This
can be done by either decreasing VEGF production or increas-
ing the removal of VEGF.
3. Laser photocoagulation
Vascular endothelial growth factor production is controlled by
oxygen tension in the tissue; the production of VEGF is in-Figure 1 This ﬁgure indicates several ways in which diabetic macula
the tissue pressure, reduces hydrostatic pressure gradient between vesse
arrows). Vitrectomy (or posterior vitreous detachment) increases oxyge
(upper right-hand arrow). Vitrectomy (or posterior vitreous detachm
increased diffusion and convection currents (upper left-hand arrow).
clearance from the retina. Retinal photocoagulation decreases outer r
retina and reduces hypoxia and VEGF production (lower arrow). Stero
proteins into the tissue and help to restore the osmotic gradient betwe
Lowering of arterial blood pressure or constriction of retinal arteriole
pressure in the microcirculation, reduces hydrostatic pressure gradient b
law (right horizontal arrow).duced by hypoxia. Perhaps the simplest way to increase the
oxygen tension in the retina is to breathe oxygen-enriched air
and Nguyen et al. (2004) have shown that breathing pure
oxygen reduces diabetic macular edema. What may be more
relevant for ophthalmologists is that retinal laser photocoagu-
lation also raises the oxygen tension in the retina and reduces
hypoxia. This has been demonstrated by four different
laboratories in more than 10 publications in a variety of
experimental animals and in humans (Stefansson, 2001, 2006,
2009; Alder et al., 1987; Budzynski et al., 2008; Diddie and
Ernest, 1977; Funatsu et al., 1997; Landers et al., 1982;
Molnar et al., 1985; Novack et al., 1990; Pournaras et al.,
1985, 1990; Stefansson et al., 1986, 1981, 1992; Yu et al.,
2005).
The laser energy is absorbed by the melanin in the reti-
nal pigment epithelium and transformed into heat which
coagulates the retinal pigment epithelium and the adjacent
photoreceptors. The destruction of the photoreceptors re-
duces the oxygen consumption of the retina and allows an
oxygen ﬂux to diffuse from the choroid through the glial la-
ser scar into the inner retina without being consumed by
the photoreceptors. This increases the oxygen tension in
the inner retina and decreases VEGF production (Alder
et al., 1987; Budzynski et al., 2008; Diddie and Ernest,
1977; Funatsu et al., 1997; Landers et al., 1982; Molnar
et al., 1985; Novack et al., 1990; Pournaras et al., 1985,
1990; Stefansson, 2006; Stefansson et al., 1986, 1981,
1992; Yu et al., 2005).r edema may be treated. Releasing vitreoretinal traction increases
l and tissue and reduces edema according to Starling’s law (central
n delivery to the retina and reduces hypoxia and VEGF production
ent) clears VEGF and other cytokines from the retina, due to
VEGF antibodies in the vitreous cavity similarly increases VEGF
etinal oxygen consumption, increases oxygen delivery to the inner
ids reduce permeability of retinal blood vessels, reduce leakage of
en blood and tissue, thus reducing edema (left horizontal arrow).
s (oxygen, photocoagulation, vitrectomy) reduces the hydrostatic
etween vessel and tissue and reduces edema according to Starling’s
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In vitrectomy the viscous vitreous gel is replaced by low viscos-
ity saline, resulting in increased transport of any molecule
within the vitreous cavity by either diffusion or convection
(Stefansson, 2009). For this reason oxygen can be transported
from well-perfused areas to non-perfused and hypoxic areas,
thus reducing retinal hypoxia in these areas. Stefansson et al.
(1990), Maeda and Tano (1996) and Holekamp et al. (2005)
have established that vitrectomy reduces retinal hypoxia in
experimental animals and humans. Removal of the vitreous
gel also allows faster transport of other molecules, such as vas-
cular endothelial growth factor, which can diffuse more readily
from the retina into the vitreous cavity, thus reducing the
VEGF concentration in the retina (Shimada et al., 2008).REDUCE 
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Figure 2 Principles of physiology and physics help to explain the com
and edema in other ischemic retinopathies, such as vein occlusions. S
osmotic and hydrostatic gradients between microcirculation and tissue.
factor (VEGF), which controls the leakage of osmotically active protei
by oxygen tension. Laser treatment, vitrectomy and oxygen breathin
production (green arrows). Vitrectomy and posterior vitreous detac
vitreous cavity and increase clearance of VEGF (and other cytokines)
VEGF antibodies in the vitreous cavity also remove VEGF from the
clearance (red arrows). The permeability effect of VEGF can be reduce
of Starling’s law is indicated by the brownish-red arrows. The hydrost
through several mechanisms. Releasing vitreoretinal traction will increa
vessel and tissue and reduce edema according to Starling’s law. Treatin
Reduction of arterial blood pressure will reduce hydrostatic pressure
between vessel and tissue and reduce edema. Improved retinal oxygen
arterioles, increases their resistance and reduces hydrostatic pressure
between vessel and tissue and edema.Vitrectomy reduces VEGF concentration both by reducing
hypoxia and VEGF production and through increased clear-
ance of cytokines from the retina into the vitreous cavity.
5. Intravitreal VEGF antibodies
The injection of VEGF antibodies, such as bevacizumab and
ranibizumab, into the vitreous cavity may have a similar con-
sequence as vitrectomy as far as VEGF clearance goes. Free
VEGF in the vitreous gel is bound by the antibody, thus low-
ering the concentration of free VEGF in the vitreous cavity
and increasing the diffusion and clearance of VEGF from
the retina, thus lowering the VEGF concentration in the ret-
ina. In addition, ranibizumab penetrates the retina and also
binds VEGF in the retina itself.AL 
ULATION
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A
bination of various treatment options for diabetic macular edema
tarling’s law governs the formation of vasogenic edema, based on
The osmotic gradient is inﬂuenced by vascular endothelial growth
ns into the tissue compartment (blue balloon). VEGF is controlled
g can increase retinal oxygen tension and thereby reduce VEGF
hment (purple arrows) increase diffusion and convection in the
from the retina, thus reducing VEFG concentration in the retina.
retinal surface and decrease VEFG concentration in the retina by
d by the administration of steroids (grey bar). The hydrostatic arm
atic gradient between microcirculation and tissue may be reduced
se the tissue pressure, reduce hydrostatic pressure gradient between
g ocular hypotony by raising intraocular pressure will do the same.
in the microcirculation, and thus reduce the hydrostatic gradient
ation through laser treatment or vitrectomy constricts the retinal
in the microcirculation, thus reducing the hydrostatic gradient
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anti VEGF antibodies may be seen as different ways to reduce
the VEGF concentration in the retina and therefore to reduce
the leakage of plasma proteins from the blood into the tissue
interstitial space.
6. Steroids
Corticosteroids such as triamcinolone and dexamethasone sta-
bilize capillaries and tend to reduce capillary leakage of plasma
proteins (Audren et al., 2006; Edelman et al., 2005; Jonas,
2005; Sorensen et al., 2005). These treatment modalities will
decrease the leakage of proteins into the interstitial tissue com-
partment and help to restore the osmotic gradient between
blood and tissue compartments. This will resolve edema
formation according to Starling’s law (Margolis et al., 2008;
Sivaprasad et al., 2006; Wang and Song, 2008).
7. Hydrostatic forces
7.1. Arterial blood pressure
Arterial hypertension is a risk factor for diabetic macular ede-
ma (Klein et al., 2009; Wong et al., 2008). Increased arterial
blood pressure increases the hydrostatic pressure in the micro-
circulation, steepens the pressure gradient between the vascula-
ture and tissue interstitial space and stimulates edema
formation according to Starling’s law. Treatment of arterial
hypertension will lower the hydrostatic pressure gradient and
thus reduce the stimulus for edema formation and this is of
course well established clinically (Klein et al., 2009; Wong
et al., 2008).
7.2. Laser photocoagulation and vitrectomy
Retinal laser photocoagulation and vitrectomy increase the
oxygen tension in the inner retina (Stefansson, 2009). In-
creased oxygen tension results in an autoregulatory vasocon-
striction, where arterioles constrict and their resistance
increases. This results in a decrease in hydrostatic pressure in
capillaries and a decrease in the hydrostatic gradient between
the vascular compartment and tissue interstitial space, thus
reducing water ﬂux from vessel to tissue and decreasing edema.
It is of interest that vasoconstriction in the retina is seen not
only following laser treatment but also following intravitreal
triamcinolone and bevacizumab injections, even though the
hydrodynamic effects of the latter are not fully understood
(Soliman et al., 2008).
7.3. Vitreoretinal traction
Vitreoretinal traction will decrease the tissue pressure in the
retina according to Newton’s third law. With lower hydrostatic
pressure in the tissue, the hydrostatic pressure gradient be-
tween the vascular and tissue compartments increases and this
stimulates water ﬂux from vessel to tissue and edema forma-
tion, much in the same way as can be seen in severe ocular
hypotony (Fig. 1). Release of the vitreoretinal traction in-
creases the hydrostatic tissue pressure again and reduces the
hydrostatic pressure gradient between the vascular and tissuecompartments, thus decreasing edema. A more detailed
description of this hypothesis of these mechanisms can be seen
in Stefansson (2009).
8. Conclusion
Through understanding of the mechanisms of the various treat-
ment modalities, which are discussed brieﬂy above
and in more detail in a recent review (Stefansson, 2009), it be-
comes possible to understand how these treatment options
work in synergy and how they can supplement each other. This
is shown graphically in Fig. 2 and explained in the ﬁgure legend.Acknowledgement
The schematics were drawn by Mr. Arni Collett.References
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